HBS-102 / Paragon Biosci, ConSynance - LARVOL DELTA

Harmony Biosciences Acquires Asset With Novel Mechanism Of Action For The Potential Treatment Of Narcolepsy And Other Rare Neurological Diseases (PRNewswire) - "Harmony Biosciences Holdings, Inc...today announced the acquisition of HBS-102 (formerly CSTI-100), a potential first-in-class molecule with a novel mechanism of action, from ConSynance Therapeutics, Inc...Harmony will acquire full development and commercialization rights globally, with the exception of Greater China, with financial terms including an upfront payment of $3.5 million and potential development and regulatory milestone payments and royalties....Harmony will complete additional work to prepare and submit an Investigational New Drug (IND) application with the plan to initiate a Phase 2 clinical trial once the IND is open."

Licensing / partnership • Cataplexy • Narcolepsy • REM Sleep Behavior Disorder • Sleep Disorder